Key Highlights

  • Wave Life Sciences (NASDAQ:WVE) rose 3.66% pre-market at an oversold RSI, with a Market Value of USD 646 million and an RSI of 22.4, on 2,525 shares, on 2,525 shares, on 2,525 shares, on 2,525 shares.
  • Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76% pre-market after a Phase 3 delay, with a market value of USD 644 million and an RSI of 20.7, on 182 shares, on 182 shares, on 182 shares, on 182 shares.
  • Aclaris Therapeutics (NASDAQ:ACRS) rose 7.46% pre-market ahead of three clinical readouts, with a market value of USD 530 million and an RSI of 29.5, on 1,051 shares, on 1,051 shares, on 1,051 shares, on 1,051 shares.
  • Prelude Therapeutics (NASDAQ:PRLD) rose 6.15% pre-market on a Partnership tag, with a market value of USD 298 million and an RSI of 33.9, on 24,721 shares, on 24,721 shares, on 24,721 shares, on 24,721 shares.

Wave Life Sciences (NASDAQ:WVE): Obesity Bet at 1.3 Times Cash

Wave Life Sciences (NASDAQ:WVE) rose 3.66% pre-market to a listed USD 3.28 on 2,525 shares, with a market Capitalization of USD 646 million and an RSI of 22.4 labeled Down, oversold. Wave Life Sciences reported second-quarter 2026 results on July 30, with Revenue of USD 2.3 million versus USD 8.7 million and a net loss of USD 69.4 million versus USD 50.5 million. Dosing is underway in the Phase 2a multidose portion of the INLIGHT trial of WVE-007, an INHBE GalNAc-siRNA, in people with obesity and a BMI of 35 to 50. Cash, cash equivalents and marketable securities were USD 490.6 million at June 30, down USD 111.5 million from year-end, and the runway into the third quarter of 2028 excludes GSK milestones. Obesity data in higher BMI patients are unproven, cash burn is rising and an oversold reading does not predict a rebound. By market value it ranks 1 of 5 in this group. What to watch next: the 600 mg INLIGHT data and the Phase 2 combination trials.

Olema Pharmaceuticals (NASDAQ:OLMA): Phase 3 Pushed to 2027

Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76% pre-market to a listed USD 7.36 on 182 shares, with a market capitalization of USD 644 million and an RSI of 20.7 labeled Down, oversold. Olema reported on August 10 that enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in second- and third-line ER-positive, HER2-negative metastatic breast cancer was complete. The top-line readout, previously expected in fall 2026, is now expected in the first quarter of 2027, which pushes the key catalyst out by several months. Cash, cash equivalents and marketable securities were USD 461.1 million at June 30, down from USD 505.3 million at March 31, a drop of USD 44.2 million in one quarter. A binary Phase 3 outcome in 2027 and rising spending keep the stock volatile, and an oversold RSI does not predict a rebound. By market value it ranks 2 of 5 in this group. What to watch next: the OPERA-01 top-line data and quarterly cash burn.

Aclaris Therapeutics (NASDAQ:ACRS): Three Readouts, Oversold Chart

Aclaris Therapeutics (NASDAQ:ACRS) rose 7.46% pre-market to a listed USD 3.60 on 1,051 shares, with a market capitalization of USD 530 million and an RSI of 29.5 labeled Down, oversold. Aclaris reported second-quarter 2026 results on August 6, with a net loss of USD 21.5 million versus USD 15.4 million a year earlier and revenue of USD 1.6 million. Full Phase 1a results for ATI-052, an anti-TSLP and IL-4 receptor Alpha bispecific antibody, showed it was well tolerated with strong, sustained pharmacokinetics and pharmacodynamics supporting up to quarterly dosing. Cash, cash equivalents and marketable securities were USD 170.6 million at June 30, and at-the-market sales since then added USD 40.2 million in gross proceeds, which extends the runway through 2028. Three binary data readouts and recurring at-the-market sales make the stock sensitive to both results and dilution. By market value it ranks 3 of 5 in this group. What to watch next: the ATI-052 Phase 1b results and the bosakitug Phase 2 readout.

Prelude Therapeutics (NASDAQ:PRLD): Below Its April Offering Price

Prelude Therapeutics (NASDAQ:PRLD) rose 6.15% pre-market to a listed USD 3.74 on 24,721 shares, with a market capitalization of USD 298 million and an RSI of 33.9 labeled Down. The screener tags a product or partnership item for Prelude, but the specific October 13 announcement was not located in company filings or wire releases reviewed. Prelude's most recent update, on August 11, showed R&D expense falling to USD 16.1 million from USD 25.8 million and net loss narrowing to USD 13.9 million from USD 31.2 million. In April 2026 the company raised USD 90.0 million at USD 4.44 a share in an offering led by RA Capital Management, and the USD 3.74 listed price is about 16% below that offer price, simple arithmetic. An IND delay, a weak early trial or another Equity raise could cut the stock, and the price sits below its April offering level. By market value it ranks 4 of 5 in this group. What to watch next: the PRT13722 IND, the partnership detail and financing.

Digital Brands Group (NASDAQ:DBGI): Tiny Float After Reverse Split

Digital Brands Group (NASDAQ:DBGI) rose 4.70% pre-market to a listed USD 3.50 on 9,088 shares, with a market capitalization of USD 3 million and an RSI of 33.7 labeled Down. Digital Brands Group, now branded DBGI Corp., is an eCommerce and fashion company that sells apparel through several brands on both a direct-to-consumer and a wholesale basis and aims to own its customers' closet share using data and purchase history. On July 17, 2026 it announced a 1-for-40 reverse stock split, effective July 24, to lift the closing bid price above USD 1.00 and manage compliance with Nasdaq Listing Rule 5550(a)(2). A float of about 557,000 shares at a USD 3.50 price implies a free-floating value of only about USD 1.9 million, simple arithmetic, so a few thousand shares can move the stock several percent. Repeated reverse splits, a tiny float and dilution risk make the stock highly volatile for a micro-cap apparel brand. By market value it ranks 5 of 5 in this group. What to watch next: the next quarterly filing, any financing and compliance with Nasdaq rules.

Where Things Stand

An RSI near or below 34 signals stretched selling, and these five rose pre-market, but oversold readings do not predict rebounds. Wave Life Sciences (NASDAQ:WVE) rose 3.66%. Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76%. Aclaris Therapeutics (NASDAQ:ACRS) rose 7.46%. Prelude Therapeutics (NASDAQ:PRLD) rose 6.15%. Digital Brands Group (NASDAQ:DBGI) rose 4.70%. Pre-market moves on thin Volume often reverse, so the balance of evidence favors waiting for the open and for filings. Direction remains unknown, and each name carries its own risks. Verify the latest filings before acting, and treat the figures as a snapshot.